Skip to Main Content

INFORMATION FOR

    Amer Zeidan, MBBS

    Professor of Internal Medicine (Hematology)
    DownloadHi-Res Photo

    Are You a Patient?

    View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    View Doctor Profile

    Additional Titles

    Chief, Hematologic Malignancies

    Director, Early Therapeutics Research, Hematology

    Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center

    Chair, Protocol Review Committee (PRC) I, Yale Cancer Center

    Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center

    Director, Hematology Research Seminar Series, Hematology

    Member, Executive Committee, Yale Cancer Center

    Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center

    About

    Titles

    Professor of Internal Medicine (Hematology)

    Chief, Hematologic Malignancies; Director, Early Therapeutics Research, Hematology; Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center; Chair, Protocol Review Committee (PRC) I, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Director, Hematology Research Seminar Series, Hematology; Member, Executive Committee, Yale Cancer Center; Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center

    Biography

    Amer Zeidan, MBBS, MHS @Dr_AmerZeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies Clinical Research Team (CRT), and the director of Continuing Medical Education (CME) at the Hematology division at Yale Cancer Center. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML).

    The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers and their therapies. Dr. Zeidan has and continues to serve as the principal investigator of many investigator-initiated, cooperative group and industry sponsored clinical trials for myeloid malignancies.

    Dr. Zeidan also chairs or serves on the steering committees of several large clinical trials of myeloid malignancies. He has served as the vice chair of the Yale Cancer Center Data and Safety Monitoring Committee (YCC DSMC) and currently serves in the independent data and safety monitoring committees of multiple clinical trials. Dr. Zeidan is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for both MDS and AML and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) in working on early phase clinical trials of novel therapies for myeloid malignancies.

    Dr. Zeidan has presented his research in many meetings and has been an invited speaker nationally and internationally. He regularly reviews abstracts for the American Society of Hematology (ASH) annual meetings and chairs meeting sessions. He has been presented on MDS in the ASH Annual highlights meetings in USA and Asia-Pacific as well as the ASH Meeting on Hematologic Malignancies. He is also active within the International Working Group (IWG) of MDS and has previously served on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines panel for MDS.

    Dr. Zeidan has received several prestigious awards including the Leukemia and Lymphoma Society Scholar in Clinical Research award, the National Cancer Institute Cancer Clinical Investigator Team Leadership award, the AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, the Tito Bastianello Young Investigator Award, the ASCO Young Investigator Award, and multiple other achievement awards. Dr. Zeidan also serves on the editorial board and is a reviewer of several important hematology and oncology journals. He is an author on more than 260 peer-reviewed publications and book chapters.

    Appointments

    • Hematology

      Associate Professor on Term
      Primary

    Other Departments & Organizations

    Education & Training

    MHS
    Johns Hopkins University (2014)
    Fellowship
    Johns Hopkins Hospital (2013)
    Internship
    Rochester General Hospital (2010)
    MBBS
    University of Jordan (2001)

    Research

    Overview

    The focus of my clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. Dr. Zeidan is the principal investigator on several clinical trials in MDS, AML and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies (drugs that stimulate the patient's own immune system) including the immune checkpoint inhibitors to fight blood cancers.

    Clinical research; Novel therapies

    Medical Research Interests

    Hematologic Neoplasms; Translational Research, Biomedical

    Research at a Glance

    Yale Co-Authors

    Frequent collaborators of Amer Zeidan's published research.

    Publications

    2024

    Clinical Trials

    Academic Achievements & Community Involvement

    • activity

      Developmental Therapeutics Research Program, Yale University

    • activity

      Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER), Yale University

    • activity

      Yale Affiliated Hospital Program

    • activity

      Yale School of Medicine Internal Medicine Residency Program

    • activity

      Blood Reviews

    Clinical Care

    Overview

    Amer Zeidan, MBBS (a medical degree awarded in several countries outside the U.S.), MHS, is a hematologist who specializes in treating and researching myeloid malignancies.

    Myeloid malignancies occur when healthy blood cells throughout the body and in bone marrow do not mature normally and instead replicate, proliferate, or transform in other ways. Dr. Zeidan’s research and clinical care focus on targeting therapies to a patient’s diagnosis and working with their own immune system to counter the malignancies.

    At Yale Cancer Center, Dr. Zeidan is the medical director of Hematology Early Therapeutics Research, leader of the Disease Aligned Research Team (DART) for Leukemia and Myeloid Malignancies, and the assistant director of the Clinical Trials Office for hematology.

    His research efforts focus on finding new, active, and safe therapies for blood cancers through clinical trials. He also explores why certain standard therapies have not been as effective in practice as they have been in clinical trials, and how the performance of these therapies can be improved in the clinic.

    Dr. Zeidan has received many awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research award and the National Cancer Institute Cancer Clinical Investigator Team Leadership award. He serves on the editorial boards of several key hematology and oncology publications, and is the author of more than 260 peer-reviewed studies and chapters of books.

    Clinical Specialties

    Hematologic Oncology; Hematology

    Fact Sheets

    Board Certifications

    • Hematology (Internal Medicine)

      Certification Organization
      AB of Internal Medicine
      Latest Certification Date
      2019
      Original Certification Date
      2013

    Yale Medicine News

    Get In Touch

    Contacts

    Appointment Number
    Clinic Fax Number

    Administrative Support

    Locations

    • 37 College Street

      Academic Office

      Fl 1, Rm 101

      New Haven, CT 06510

    • Patient Care Locations

      Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.